(Senior) Director, Portfolio Strategy, Life Sciences

Your Impact at LILA

Lila Sciences is hiring a Director / Senior Director, New Product Planning to help shape Lila Origins, our company and asset creation arm which partners to translate scientific vision into molecules, materials, and real-world ventures. As a member of a small, highly cross-functional team, you will bring the commercial voice to life sciences opportunities at the earliest stages, assessing where Lila's platform can produce differentiated assets and shaping how those opportunities become ventures, partnerships, or programs.

You will spend your time at the interface of science, market, and deal structure. You will match therapeutic modalities to disease areas based on biological fit, competitive landscape, and commercial viability. You will build quantitative views of opportunities (market sizing, patient population modeling, deal economics) and translate them into recommendations for Origins and Lila leadership. You will pressure-test ideas with external operators, investors, and partners, and use what you learn to sharpen Lila's Origins thesis.

This role suits someone who has run new product planning, asset strategy, or commercial assessment work inside a pharma or biotech organization, lives close to industry trends, and is drawn to a builder environment where the asset list is being defined in real time. You will work closely with the VP, Head of Lila Origins, and sit within Corporate Development. The work is high ambiguity, high leverage, and deliberately cross-disciplinary.

What You'll Be Building

• Source and evaluate new life sciences opportunities for Origins, screening for scientific differentiation, commercial viability, and fit with Lila's platform capabilities
• Track therapeutic area trends, modality breakthroughs, pipeline movement, and deal activity across pharma and biotech, and translate signal into actionable views for Origins
• Match therapeutic modalities to disease areas using biological rationale, competitive landscape, and unmet need, and recommend where Origins should concentrate effort
• Build and own market sizing, patient population, and deal economic models that inform go / no-go decisions on candidate ventures and partnerships
• Develop target product profiles and early commercial theses for assets under consideration, in partnership with Science, Product, and Corporate Development
• Run primary and secondary research (KOL interviews, competitor tracking, payer and clinician landscape) to stress-test assumptions and sharpen recommendations
• Shape deal structures and partnership constructs alongside Corporate Development, translating commercial logic into terms that work for Lila and counterparties
• Contribute to Origins' strategic thesis by synthesizing what we learn across opportunities into recommendations on therapeutic area focus, modality bets, and partnership models

What You'll Need to Succeed

• 6-8+ years in new product planning, commercial assessment, asset strategy, or business development inside a pharma, biotech, or life sciences investor (VC, growth equity) setting, with a track record of shaping go / no-go calls on early assets
• Strong scientific literacy in life sciences (therapeutics, modalities, disease biology); able to engage substantively with Science and external KOLs and translate scientific nuance into commercial implications
• Demonstrated ability to match therapeutic modalities to disease areas, with a clear point of view on where biological fit, unmet need, and competitive landscape converge
• Hands-on modeling experience: market sizing, patient population, forecasting, deal economics; comfortable building models from scratch and defending assumptions
• Active fluency in industry trends, pipeline movement, and deal activity across pharma and biotech; reads the market without needing a research function to brief you
• Strong written and verbal communication; able to distill complex commercial and scientific analyses into crisp recommendations for senior leadership
• Comfort operating in high ambiguity with limited oversight; biased toward building structure where none exists

Bonus Points For

• Advanced degree in life sciences (PhD, MS in biology, chemistry, bioengineering) or an MBA with deep life sciences focus
• Network of biotech operators, VCs, KOLs, and pharma BD leaders that you can tap for diligence and signal
• Hands-on use of AI tools in your workflows (market research, competitor tracking, modeling, synthesis) and a clear point of view on how AI is reshaping drug discovery and asset creation
• Prior experience structuring or evaluating partnership models, joint ventures, or NewCo formation